Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca plc (AZN)
Price£120.06Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B | $24.38B | $22.09B | $22.46B | $23.00B | $24.71B |
| Gross profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B | $19.46B | $17.15B | $18.15B | $18.88B | $20.06B |
| Gross margin | 81.90% | 81.12% | 81.95% | 72.06% | 66.76% | 80.09% | 79.82% | 77.66% | 80.78% | 82.06% | 81.20% |
| Research & development | $14.23B | $13.58B | $10.94B | $9.76B | $9.74B | $5.99B | $6.06B | $5.93B | $5.76B | $5.89B | $6.00B |
| Operating expenses | $34.36B | $33.86B | $29.35B | $28.20B | $23.92B | $16.16B | $16.54B | $13.77B | $14.47B | $13.97B | $15.95B |
| Operating income | $13.74B | $10.00B | $8.19B | $3.76B | $1.06B | $5.16B | $2.92B | $3.39B | $3.68B | $4.90B | $4.11B |
| Operating margin | 23.40% | 18.50% | 17.88% | 8.47% | 2.82% | 19.39% | 11.99% | 15.33% | 16.37% | 21.31% | 16.65% |
| EBITDA | $18.83B | $14.72B | $12.85B | $9.09B | — | — | — | — | — | — | — |
| EBITDA margin | 32.06% | 27.23% | 28.05% | 20.48% | — | — | — | — | — | — | — |
| Net income | $10.23B | $7.04B | $5.96B | $3.29B | $115.0M | $3.14B | $1.23B | $2.05B | $2.87B | $3.41B | $2.83B |
| Net profit margin | 17.42% | 13.02% | 13.01% | 7.42% | 0.31% | 11.81% | 5.03% | 9.28% | 12.77% | 14.81% | 11.44% |
| Basic EPSper basic share | $6.60 | $4.54 | $3.84 | $2.12 | $0.08 | $2.44 | $1.03 | $1.70 | $2.37 | $2.77 | $2.23 |
| Diluted EPSper diluted share | $6.54 | $4.50 | $3.81 | $2.11 | $0.08 | $2.44 | $1.03 | $1.70 | $2.37 | $2.76 | $2.23 |
Owners
Reported major voting-rights holders
4.31%of voting rights
The Capital Group Companies, Inc.Notified Dec 2, 2025
View holders
| Holder | Voting rights |
|---|---|
The Capital Group Companies, Inc. | 4.31%Dec 2, 2025 · 66.77M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA National Storage Mechanism ↗Updated Sep 27, 2026
Insider buys & sells
Community posts
AstraZeneca receives priority review for perioperative bladder-cancer regimen
The FDA granted priority review to a regimen combining AstraZeneca ($AZN)’s Imfinzi with enfortumab vedotin around surgery for muscle-invasive bladder cancer in patients ineligible for, or declining, cisplatin chemotherapy. Imfinzi is given ...
AstraZeneca’s Klygefa receives a positive EU recommendation
European medicines advisers recommended AstraZeneca ($AZN)’s Klygefa, or gefurulimab, as an add-on to standard treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The Alexion ...
Enhertu receives European recommendation for an earlier breast-cancer setting
European advisers recommended Enhertu for postoperative treatment of adults with HER2-positive breast cancer who still have invasive disease after preoperative taxane-based chemotherapy and HER2-directed treatment. The drug is jointly devel ...
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...
